The DIAAMOND Trial presented at International Conferences

In 2022, the DIAAMOND Trial was presented on the international setting at both the American Society of Hematology Annual Meeting (New Orleans) and European School of Haematology EBMT Translational Research Conference (Paris). The trial was well received by international colleagues.

“Trial in Progress: Efficacy and Safety of Avatrombopag in Combination with Immunosuppressive Therapy in Treatment-Naïve and Relapsed/Refractory Severe Aplastic Anaemia – the DiAAMOND-Ava-First and DiAAMOND-Ava-Next, Bayesian Optimal Phase II Trials”


The DIAAMOND clinical trial is open to recruitment at 12 sites and has recruited 71 both newly diagnosed and refractory/relapsed patients since opening in October 2019.
For more information about the trial and how to participate,  please refer to the Clinical Trial page or contact us via phone or email.
If you are a patient and are interested in participating in the DIAAMOND trial, please speak to your treating clinician.

New name for the Aplastic Anaemia Registry

The registry has expanded the name from the Aplastic Anaemia Registry to the Aplastic Anaemia Registry and Other Bone Marrow Failure Syndromes to reflect the expansion of scope to include all BMFS.